[8-K] Helius Medical Technologies, Inc. Reports Material Event
On July 7, 2025, Helius Medical Technologies, Inc. (NASDAQ: HSDT) received formal notice from The Nasdaq Stock Market LLC confirming that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders鈥� equity of $2.5 million. The company had already restored compliance with the minimum bid-price rule 5550(a)(2) on June 3, 2025. As a result, Helius now meets all criteria necessary to maintain its listing on the Nasdaq Capital Market.
Under Nasdaq Listing Rule 5815(d)(4)(B), HSDT will be subject to a Mandatory Panel Monitor until July 7, 2026. If the company falls out of equity compliance during this one-year period, it will receive an immediate delist determination without the usual cure period, although it may request a new hearing.
No additional financial results, transactions, or operational updates were provided in this Form 8-K.
Il 7 luglio 2025, Helius Medical Technologies, Inc. (NASDAQ: HSDT) ha ricevuto una comunicazione ufficiale da The Nasdaq Stock Market LLC che conferma di aver ripristinato la conformit脿 alla Regola di Quotazione Nasdaq 5550(b)(1), la quale richiede un patrimonio netto minimo di 2,5 milioni di dollari. L'azienda aveva gi脿 rispettato la regola del prezzo minimo di offerta 5550(a)(2) il 3 giugno 2025. Di conseguenza, Helius soddisfa ora tutti i requisiti necessari per mantenere la propria quotazione sul Nasdaq Capital Market.
Secondo la Regola di Quotazione Nasdaq 5815(d)(4)(B), HSDT sar脿 soggetta a un Monitoraggio Obbligatorio da parte di un Panel fino al 7 luglio 2026. Se durante questo periodo di un anno la societ脿 dovesse perdere la conformit脿 patrimoniale, sar脿 immediatamente soggetta a una decisione di esclusione dalla quotazione senza il consueto periodo di recupero, anche se potr脿 richiedere una nuova audizione.
In questo modulo 8-K non sono stati forniti ulteriori risultati finanziari, transazioni o aggiornamenti operativi.
El 7 de julio de 2025, Helius Medical Technologies, Inc. (NASDAQ: HSDT) recibi贸 una notificaci贸n formal de The Nasdaq Stock Market LLC que confirma que ha recuperado el cumplimiento con la Regla de Cotizaci贸n Nasdaq 5550(b)(1), la cual requiere un patrimonio neto m铆nimo de 2,5 millones de d贸lares. La compa帽铆a ya hab铆a restablecido el cumplimiento con la regla del precio m铆nimo de oferta 5550(a)(2) el 3 de junio de 2025. Como resultado, Helius ahora cumple con todos los criterios necesarios para mantener su cotizaci贸n en el Nasdaq Capital Market.
Bajo la Regla de Cotizaci贸n Nasdaq 5815(d)(4)(B), HSDT estar谩 sujeta a un Monitoreo Obligatorio por un Panel hasta el 7 de julio de 2026. Si la compa帽铆a pierde el cumplimiento patrimonial durante este per铆odo de un a帽o, recibir谩 una determinaci贸n inmediata de exclusi贸n sin el per铆odo habitual de correcci贸n, aunque podr谩 solicitar una nueva audiencia.
No se proporcionaron resultados financieros adicionales, transacciones ni actualizaciones operativas en este Formulario 8-K.
2025雲� 7鞗� 7鞚�, Helius Medical Technologies, Inc. (NASDAQ: HSDT)電� The Nasdaq Stock Market LLC搿滊秬韯� 雮橃姢雼� 靸侅灔 攴滌箼 5550(b)(1) 欷�靾� 須岆车鞚� 瓿奠嫕 韱奠氚涭晿鞀惦媹雼�. 鞚� 攴滌箼鞚� 斓滌唽 鞛愱赴鞛愲掣 250毵� 雼煬毳� 鞖旉惮頃╇媹雼�. 須岇偓電� 鞚措 2025雲� 6鞗� 3鞚检棎 斓滌唽 鞛呾鞍臧� 攴滌箼 5550(a)(2) 欷�靾橂ゼ 須岆车頃� 氚� 鞛堨姷雼堧嫟. 鞚挫棎 霐半澕 Helius電� 雮橃姢雼� 鞛愲掣鞁滌灔 靸侅灔鞚� 鞙犾頃橂姅 雿� 頃勳殧頃� 氇摖 旮办鞚� 於╈”頃橁矊 霅橃棃鞀惦媹雼�.
雮橃姢雼� 靸侅灔 攴滌箼 5815(d)(4)(B)鞐� 霐半澕, HSDT電� 2026雲� 7鞗� 7鞚缄箤歆� 鞚橂 韺剱 氇媹韯半鞚� 氚涥矊 霅╇媹雼�. 鞚� 1雲� 旮瓣皠 霃欖晥 鞛愱赴鞛愲掣 旮办鞚� 氩楈柎雮橂┐, 鞚茧皹鞝侅澑 鞁滌爼 旮瓣皠 鞐嗢澊 歃夓嫓 靸侅灔韽愳 瓴办爼鞚� 雮措牑歆�氅�, 雼る 鞛嫭 觳惮電� 臧�電ロ暕雼堧嫟.
氤� 8-K 鞏戩嫕鞐愲姅 於旉皜鞝侅澑 鞛 瓴瓣臣, 瓯半灅 霕愲姅 鞖挫榿 甏�霠� 鞐呺嵃鞚错姼臧� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Le 7 juillet 2025, Helius Medical Technologies, Inc. (NASDAQ : HSDT) a re莽u une notification formelle de The Nasdaq Stock Market LLC confirmant qu鈥檈lle a r茅tabli sa conformit茅 脿 la r猫gle de cotation Nasdaq 5550(b)(1), qui exige un fonds propres minimum de 2,5 millions de dollars. La soci茅t茅 avait d茅j脿 r茅tabli la conformit茅 脿 la r猫gle du prix d鈥檕ffre minimum 5550(a)(2) le 3 juin 2025. Par cons茅quent, Helius remplit d茅sormais tous les crit猫res n茅cessaires pour maintenir sa cotation sur le Nasdaq Capital Market.
Conform茅ment 脿 la r猫gle de cotation Nasdaq 5815(d)(4)(B), HSDT sera soumise 脿 un Contr么le Obligatoire par un Panel jusqu鈥檃u 7 juillet 2026. Si la soci茅t茅 venait 脿 ne plus respecter les exigences en mati猫re de fonds propres durant cette p茅riode d鈥檜n an, une d茅cision imm茅diate de radiation serait prise sans la p茅riode habituelle de redressement, bien qu鈥檈lle puisse demander une nouvelle audience.
Aucun r茅sultat financier suppl茅mentaire, transaction ou mise 脿 jour op茅rationnelle n鈥檃 茅t茅 communiqu茅 dans ce formulaire 8-K.
Am 7. Juli 2025 erhielt Helius Medical Technologies, Inc. (NASDAQ: HSDT) eine formelle Mitteilung von The Nasdaq Stock Market LLC, die best盲tigt, dass das Unternehmen die Einhal颅tung der Nasdaq-Listing-Regel 5550(b)(1) wiederhergestellt hat, welche ein Mindestaktion盲rskapital von 2,5 Millionen US-Dollar vorschreibt. Bereits am 3. Juni 2025 hatte das Unternehmen die Einhaltung der Mindestgebotspreisregel 5550(a)(2) wiederhergestellt. Somit erf眉llt Helius nun alle Voraussetzungen, um seine Notierung am Nasdaq Capital Market aufrechtzuerhalten.
Gem盲脽 Nasdaq-Listing-Regel 5815(d)(4)(B) unterliegt HSDT bis zum 7. Juli 2026 einer Verpflichtenden Panel-脺berwachung. Sollte das Unternehmen w盲hrend dieses Einjahreszeitraums erneut die Eigenkapitalanforderungen nicht erf眉llen, erfolgt eine sofortige Delisting-Entscheidung ohne die 眉bliche Nachfrist, wobei jedoch eine erneute Anh枚rung beantragt werden kann.
In diesem Formular 8-K wurden keine weiteren finanziellen Ergebnisse, Transaktionen oder operative Aktualisierungen mitgeteilt.
- Regained compliance with Nasdaq鈥檚 $2.5 million stockholders鈥� equity requirement, securing continued listing
- Previously restored compliance with minimum bid-price rule, fully meeting Nasdaq Capital Market standards
- Company placed under one-year Mandatory Panel Monitor; any future equity shortfall will prompt immediate delisting proceedings
- Filing does not disclose the exact stockholders鈥� equity figure, limiting visibility into compliance buffer
Insights
TL;DR: Listing compliance restored; delisting risk deferred but one-year probation increases vigilance.
Helius鈥檚 confirmation of equity compliance removes an immediate overhang that threatened liquidity and institutional ownership constraints. Regaining both the equity and bid-price standards keeps the shares tradable on Nasdaq, a net positive for market perception and access to capital. However, the Mandatory Panel Monitor until July 2026 means any dip below the $2.5 million equity threshold will trigger a delist determination with no grace period, underscoring the company鈥檚 limited margin for error. Investors should monitor forthcoming balance-sheet disclosures to ensure equity remains comfortably above the floor. Overall impact is positive, but sustainability of compliance remains a key risk factor.
Il 7 luglio 2025, Helius Medical Technologies, Inc. (NASDAQ: HSDT) ha ricevuto una comunicazione ufficiale da The Nasdaq Stock Market LLC che conferma di aver ripristinato la conformit脿 alla Regola di Quotazione Nasdaq 5550(b)(1), la quale richiede un patrimonio netto minimo di 2,5 milioni di dollari. L'azienda aveva gi脿 rispettato la regola del prezzo minimo di offerta 5550(a)(2) il 3 giugno 2025. Di conseguenza, Helius soddisfa ora tutti i requisiti necessari per mantenere la propria quotazione sul Nasdaq Capital Market.
Secondo la Regola di Quotazione Nasdaq 5815(d)(4)(B), HSDT sar脿 soggetta a un Monitoraggio Obbligatorio da parte di un Panel fino al 7 luglio 2026. Se durante questo periodo di un anno la societ脿 dovesse perdere la conformit脿 patrimoniale, sar脿 immediatamente soggetta a una decisione di esclusione dalla quotazione senza il consueto periodo di recupero, anche se potr脿 richiedere una nuova audizione.
In questo modulo 8-K non sono stati forniti ulteriori risultati finanziari, transazioni o aggiornamenti operativi.
El 7 de julio de 2025, Helius Medical Technologies, Inc. (NASDAQ: HSDT) recibi贸 una notificaci贸n formal de The Nasdaq Stock Market LLC que confirma que ha recuperado el cumplimiento con la Regla de Cotizaci贸n Nasdaq 5550(b)(1), la cual requiere un patrimonio neto m铆nimo de 2,5 millones de d贸lares. La compa帽铆a ya hab铆a restablecido el cumplimiento con la regla del precio m铆nimo de oferta 5550(a)(2) el 3 de junio de 2025. Como resultado, Helius ahora cumple con todos los criterios necesarios para mantener su cotizaci贸n en el Nasdaq Capital Market.
Bajo la Regla de Cotizaci贸n Nasdaq 5815(d)(4)(B), HSDT estar谩 sujeta a un Monitoreo Obligatorio por un Panel hasta el 7 de julio de 2026. Si la compa帽铆a pierde el cumplimiento patrimonial durante este per铆odo de un a帽o, recibir谩 una determinaci贸n inmediata de exclusi贸n sin el per铆odo habitual de correcci贸n, aunque podr谩 solicitar una nueva audiencia.
No se proporcionaron resultados financieros adicionales, transacciones ni actualizaciones operativas en este Formulario 8-K.
2025雲� 7鞗� 7鞚�, Helius Medical Technologies, Inc. (NASDAQ: HSDT)電� The Nasdaq Stock Market LLC搿滊秬韯� 雮橃姢雼� 靸侅灔 攴滌箼 5550(b)(1) 欷�靾� 須岆车鞚� 瓿奠嫕 韱奠氚涭晿鞀惦媹雼�. 鞚� 攴滌箼鞚� 斓滌唽 鞛愱赴鞛愲掣 250毵� 雼煬毳� 鞖旉惮頃╇媹雼�. 須岇偓電� 鞚措 2025雲� 6鞗� 3鞚检棎 斓滌唽 鞛呾鞍臧� 攴滌箼 5550(a)(2) 欷�靾橂ゼ 須岆车頃� 氚� 鞛堨姷雼堧嫟. 鞚挫棎 霐半澕 Helius電� 雮橃姢雼� 鞛愲掣鞁滌灔 靸侅灔鞚� 鞙犾頃橂姅 雿� 頃勳殧頃� 氇摖 旮办鞚� 於╈”頃橁矊 霅橃棃鞀惦媹雼�.
雮橃姢雼� 靸侅灔 攴滌箼 5815(d)(4)(B)鞐� 霐半澕, HSDT電� 2026雲� 7鞗� 7鞚缄箤歆� 鞚橂 韺剱 氇媹韯半鞚� 氚涥矊 霅╇媹雼�. 鞚� 1雲� 旮瓣皠 霃欖晥 鞛愱赴鞛愲掣 旮办鞚� 氩楈柎雮橂┐, 鞚茧皹鞝侅澑 鞁滌爼 旮瓣皠 鞐嗢澊 歃夓嫓 靸侅灔韽愳 瓴办爼鞚� 雮措牑歆�氅�, 雼る 鞛嫭 觳惮電� 臧�電ロ暕雼堧嫟.
氤� 8-K 鞏戩嫕鞐愲姅 於旉皜鞝侅澑 鞛 瓴瓣臣, 瓯半灅 霕愲姅 鞖挫榿 甏�霠� 鞐呺嵃鞚错姼臧� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Le 7 juillet 2025, Helius Medical Technologies, Inc. (NASDAQ : HSDT) a re莽u une notification formelle de The Nasdaq Stock Market LLC confirmant qu鈥檈lle a r茅tabli sa conformit茅 脿 la r猫gle de cotation Nasdaq 5550(b)(1), qui exige un fonds propres minimum de 2,5 millions de dollars. La soci茅t茅 avait d茅j脿 r茅tabli la conformit茅 脿 la r猫gle du prix d鈥檕ffre minimum 5550(a)(2) le 3 juin 2025. Par cons茅quent, Helius remplit d茅sormais tous les crit猫res n茅cessaires pour maintenir sa cotation sur le Nasdaq Capital Market.
Conform茅ment 脿 la r猫gle de cotation Nasdaq 5815(d)(4)(B), HSDT sera soumise 脿 un Contr么le Obligatoire par un Panel jusqu鈥檃u 7 juillet 2026. Si la soci茅t茅 venait 脿 ne plus respecter les exigences en mati猫re de fonds propres durant cette p茅riode d鈥檜n an, une d茅cision imm茅diate de radiation serait prise sans la p茅riode habituelle de redressement, bien qu鈥檈lle puisse demander une nouvelle audience.
Aucun r茅sultat financier suppl茅mentaire, transaction ou mise 脿 jour op茅rationnelle n鈥檃 茅t茅 communiqu茅 dans ce formulaire 8-K.
Am 7. Juli 2025 erhielt Helius Medical Technologies, Inc. (NASDAQ: HSDT) eine formelle Mitteilung von The Nasdaq Stock Market LLC, die best盲tigt, dass das Unternehmen die Einhal颅tung der Nasdaq-Listing-Regel 5550(b)(1) wiederhergestellt hat, welche ein Mindestaktion盲rskapital von 2,5 Millionen US-Dollar vorschreibt. Bereits am 3. Juni 2025 hatte das Unternehmen die Einhaltung der Mindestgebotspreisregel 5550(a)(2) wiederhergestellt. Somit erf眉llt Helius nun alle Voraussetzungen, um seine Notierung am Nasdaq Capital Market aufrechtzuerhalten.
Gem盲脽 Nasdaq-Listing-Regel 5815(d)(4)(B) unterliegt HSDT bis zum 7. Juli 2026 einer Verpflichtenden Panel-脺berwachung. Sollte das Unternehmen w盲hrend dieses Einjahreszeitraums erneut die Eigenkapitalanforderungen nicht erf眉llen, erfolgt eine sofortige Delisting-Entscheidung ohne die 眉bliche Nachfrist, wobei jedoch eine erneute Anh枚rung beantragt werden kann.
In diesem Formular 8-K wurden keine weiteren finanziellen Ergebnisse, Transaktionen oder operative Aktualisierungen mitgeteilt.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| ||
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
On July 7, 2025, Helius Medical Technologies, Inc. (the “Company”) received formal notification (the “Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires issuers listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2.5 million (the “Equity Requirement”).
As previously disclosed, following a hearing with the Nasdaq Hearing Panel (the “Panel”) on March 18, 2025, on April 1, 2025, the Company received a decision letter from the Panel, granting the Company’s request to continue its listing on Nasdaq, subject demonstrating compliance with both the minimum bid price requirement, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) and the Equity Requirement prior to June 30, 2025. On June 3, 2025, the Company received formal notification from Nasdaq confirming that the Company had regained compliance with the Minimum Bid Price Requirement. Consequently, following receipt of the Notification, the Company is now in compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.
Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor until July 7, 2026. If, within that one-year monitoring period, the Nasdaq Listing Qualifications staff (the “Staff”) finds the Company again out of compliance with the Equity Requirement, notwithstanding Nasdaq Listing Rule 5810(c)(2), the Company would not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and the Staff would not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor would the Company be afforded an applicable cure or compliance period pursuant to Nasdaq Listing Rule 5810(c)(3). Instead, the Staff would issue a “Delist Determination Letter” and the Company would have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HELIUS MEDICAL TECHNOLOGIES, INC. | ||
|
|
|
|
Dated: July 9, 2025 |
| By: | /s/ Jeffrey S. Mathiesen |
|
|
| Jeffrey S. Mathiesen |
|
|
| Chief Financial Officer, Treasurer and Secretary |
3
Source:
FAQ
What did Helius Medical Technologies (HSDT) announce on July 7, 2025?
Which Nasdaq rules has HSDT now satisfied?
How long will HSDT be monitored by Nasdaq?
What happens if HSDT falls below the equity requirement during the monitor period?
Does this 8-K include any earnings or financial results?
